Paper Details

  1. Home
  2. Paper Details

Effect of RNS60 in amyotrophic lateral sclerosis: a phase II multicentre, randomized, double-blind, placebo-controlled trial.

Author: , BeghiEttore, BendottiCaterina, BianchiElisa, BonettoValentina, BongioanniPaolo, CalvoAndrea, CamporealeLaura, CaponnettoClaudia, CarboniNicola, ConteAmelia, Dalla GiacomaStefania, De AngelisNicoletta, De MarchiFabiola, Del CarratoreRenata, DiamantiLuca, FilippiMassimo, FilostoMassimiliano, FlorioLucia, InghilleriMaurizio, La BellaVincenzo, LogroscinoGiancarlo, LunettaChristian, LuottiSilvia, MandrioliJessica, MartinelliDaniele, MartinelliIlaria, MazziniLetizia, MessinaSonia, MonsurròMaria Rosaria, PadovaniAlessandro, PaganoniSabrina, PasettoLaura, PiccinelliStefano Cotti, PupilloElisabetta, RicciClaudia, RicciardiDario, RivaNilo, RussoMassimo, SaddiMaria Valeria, ScognamiglioAda, ShermanAlexander V, SicilianoGabriele, SimoneIsabella Laura, SimoniniCecilia, SironiFrancesca, SorarùGianni, SpataroRossella, SperaCristina, TarlariniClaudia, TortaroloMassimo, TrojsiFrancesca, ZucchiElisabetta

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Amyotrophic lateral sclerosis (ALS) is a fatal disease with limited treatment options. This study highlights a new treatment, RNS60, which has shown promise in animal studies and early human trials for ALS and other neurological diseases. RNS60 has a good safety profile and seems well-tolerated by patients with ALS.
Paper Details　
Original Abstract of the Article :
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with limited treatment options. RNS60 is an immunomodulatory and neuroprotective investigational product that has shown efficacy in animal models of ALS and other neurodegenerative diseases. Its administration has been safe and...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092300/

データ提供：米国国立医学図書館（NLM）

RNS60: A Potential Oasis in the ALS Desert

This research takes us into the world of Amyotrophic Lateral Sclerosis (ALS), a debilitating neurodegenerative disease that's like a relentless desert storm, slowly eroding away at a person's ability to move. The study investigates the potential of RNS60, an immunomodulatory and neuroprotective investigational product, as a possible treatment for ALS. RNS60 is like a traveler seeking a hidden oasis in the heart of the desert, offering hope for those struggling with this devastating disease.

A Promising Oasis for ALS Patients

The study delves into the potential benefits of RNS60 in ALS patients, exploring its safety, efficacy, and tolerability. This is akin to a caravan carefully assessing a newly discovered oasis, examining its water quality and potential hazards before allowing its weary camels to rest and drink. Previous early-phase trials demonstrated that RNS60 is safe and well tolerated in ALS subjects, offering a promising sign for future research. The study's findings, like a beacon in the desert, suggest that RNS60 could potentially be a valuable tool in the fight against ALS, offering hope for those seeking respite from this relentless disease.

The Journey Towards a Cure for ALS

The study highlights the ongoing quest for effective treatments for ALS, a journey through a vast and unforgiving desert. While RNS60 shows promise, it is important to note that it is still in the early stages of research. This underscores the need for further investigation to fully understand its potential benefits and risks, much like a camel caravan meticulously mapping a new route through the desert. The fight against ALS is a long and arduous journey, but this research offers a glimpse of hope, a potential oasis in a seemingly endless desert.

Dr. Camel's Conclusion

This research explores the potential of RNS60 as a treatment for ALS, a condition that's like a desert storm slowly eroding away at a person's strength and mobility. While RNS60 is still in the early stages of research, the study's findings offer a glimmer of hope, like a mirage in the desert that could eventually lead to a life-changing oasis for those struggling with ALS.

Date :
  1. Date Completed 2022-12-16
  2. Date Revised 2023-04-15
Further Info :

Pubmed ID

36148821

DOI: Digital Object Identifier

PMC10092300

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.